Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates

Kura Oncology (KURA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of$ 0.63. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 65.08%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.64 per share when it actually produced a loss of $0.63, delivering a surprise of 1.56%.Over the last four quarters, the compa ...